According to the invention of this patent disclosure, the compounds are useful in the treatment of neurodegenerative disorders like Alzheimer’s, Parkinson, Schizophrenia and Huntington’s.
Venkat Jasti, CEO of Suven, said: “We are very pleased by the issuance of this patent to Suven by US Patent office for our drug candidates that are being developed for CNS disorders which targets a $18 billion potential market opportunity.”